Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

PHARMA MAR SA (PHM) EUR0.6

Sell:€75.84 Buy:€75.94 Change: €1.70 (2.19%)
IBEX 35:0.00%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€75.84
Buy:€75.94
Change: €1.70 (2.19%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€75.84
Buy:€75.94
Change: €1.70 (2.19%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.

Contact details

Address:
Avda. De los Reyes, 1, Pol. Ind. La Mina
COLMENAR VIEJO
28770
Spain
Telephone:
+34 (918) 466000
Website:
https://www.pharmamar.com/es/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PHM
ISIN:
ES0169501022
Market cap:
€1.43 billion
Shares in issue:
18.11 million
Sector:
Biotechnology
Exchange:
Madrid Stock Exchange
Country:
Spain
Currency:
Euro
Indices:
IBEX 35

Key personnel

  • Jose Maria Fernandez Sousa-Faro
    President, Chief Executive Officer, Executive Chairman of the Board
  • Pedro Francisco Fernandez Puentes
    Executive Vice Chairman
  • Maria Luisa de Francia Caballero
    Chief Financial Officer
  • Jose Maria Jimeno
    Vice President - Global Head Virus & Inflammation
  • Carmen Cuevas Marchante
    Director - Research & Development
  • Heiner Pieper
    Vice President - Business Development & Licensing
  • Juan Gomez Pulido
    General Counsel and Secretary of the Board of Directors
  • Luis Mora Capitan
    Managing Director - Oncology & Virology Business Units
  • Juan Nogues Ortuno
    Director - International Sales and Marketing
  • Jose Luis Moreno Martinez-Losa
    Director of Capital Markets and Investor Relations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.